The upgrade in the price target by Chardan Capital, a reputable analyst firm, suggests a positive outlook on Coya Therapeutics' stock. This is likely to instill confidence in investors and could lead to a short-term increase in the stock price. The direct mention of COYA with a raised price target and maintained Buy rating indicates a strong bullish sentiment from the analyst, which often influences investor behavior positively.